2026年2月27日，国家药品监督管理局公布了 创新医疗器械特别审查申请审查结果公示（2026年第4号） ， 有 4款产品 进入创新通道 。 | | | 2. 神经外科手术导航系统 申请人 ：北京联影智融医疗科技有限公司 北京联影智融医疗科技有限公司是联影医疗技术集团旗下医疗科技企业，致力于为临床提供创新医疗产品与解决方案。公司聚焦预防、诊断、治疗和康复等临床应 用场景，通过自主研发和产业化推进智能医疗设备及系统的落地，包括手术导航系统、辅助设备及智能诊疗系统等，服务医院临床和医生诊疗工作。联影智融在联 影集团医疗生态框架支持下，旨在提升医疗科技整体能力，推动智能医疗应用在全球范围的普及。 1.胰腺病变CT图像辅助分诊软件 申请人 ： 阿里巴巴达摩院（北京）科技有限公司 阿里巴巴达摩院（北京）科技有限公司成立于2017年11月，是阿里巴巴集团设立的科研与技术创新机构，在北京注册登记运营，主营科技推广与应用服务。达摩院 以"探索科技未知、以人类愿景为驱动力"为使命，聚焦基础科学和前沿技术研究，在人工智能、机器学习、数据计算、视觉计算等核心领域开展长期研发，并推动 科研成果向产业实践和产品化落地。达摩院在医疗影像 ...

DeepRare的在线诊断平台已于2025年7月26日上线，半年内吸引超1000名全球专业用户注册，覆盖600多 家医疗及科研机构。目前，该系统已在新华医院完成部署并内测，将作为"数字质控员"纳入全院罕见病 诊疗质控流程；团队与国内头部基因检测机构深度合作，实现临床解读报告自动化生成，降低基因检测 解读的成本与门槛。 目前，联合团队已启动"万人临床验证计划"，将依托国际多中心合作完成数万例疑难罕见病临床验证， 编织全球智能诊断网。 23日，记者从上海交通大学获悉，该校人工智能学院与医学院附属新华医院联合团队，推出全球首个智 能体式罕见病循证推理诊断系统DeepRare，为罕见病"确诊难、漏诊率高"的全球性难题提供了中国解决 方案。相关研究成果在线发表于国际期刊《自然》。 DeepRare由上海交通大学张娅教授、谢伟迪副教授与新华医院孙锟教授、余永国教授领衔攻关，创新性 采用"中枢—分身"架构，实现对传统医学AI的代际超越。该系统整合海量医学文献与临床病例，实现知 识深度内化；摒弃传统AI的模式匹配，通过"假设—验证—自我反思"的类人类"慢思考"能力推敲诊断线 索；实现了全流程循证的"白盒推理"，每一个诊断结论 ...

Group 1 - The "Xiehe Innovation Port" project was officially launched on February 2, with a cooperation agreement signed between the Chinese Academy of Medical Sciences Peking Union Medical College and the Dongcheng District government [2][3] - The project aims to focus on key areas such as innovative drugs, new vaccines, high-end medical devices, and artificial intelligence in healthcare, creating a benchmark innovation platform that integrates achievement transformation, industry incubation, resource docking, talent cultivation, and professional services [6] - The cooperation agreement includes five core components: provision of physical space and supporting services by Dongcheng District, special support policies, establishment of an integrated platform for technology breakthroughs and achievement transformation, creation of a talent cultivation base, and a governance model ensuring efficient operation [6][7]

Core Viewpoint - The company has strategically invested in Hangzhou Haoshi Tianhui Technology Co., Ltd., acquiring a 16% stake as the sole investor in its latest financing round, marking another exploration in the non-invasive brain-computer interface sector following its 2025 investment in Qingshi Yongjuan [1] Group 1: Company Overview - Haoshi Tianhui is an innovative high-tech enterprise focused on artificial intelligence in the medical field, with a founding team that has overseas entrepreneurial experience and strong industry expertise [1] - The company has developed a diverse product matrix that includes applications in mental health, cardiovascular monitoring, and imaging diagnostics [1] Group 2: Product and Technology - Haoshi Tianhui's self-developed medical-grade non-invasive brain-computer interface and mental health assessment devices can accurately evaluate emotional issues such as depression and anxiety, integrating music therapy interventions into a comprehensive service model [1] - The products are designed for various settings, including hospitals, schools, health check centers, and mental health institutions, providing objective and efficient assessments compared to traditional evaluation methods [1] Group 3: Regulatory and Market Plans - The company obtained a Class II medical device registration certificate in November 2025 for its products aimed at detecting mental health issues, with plans to promote and sell these products in the domestic market starting in 2026 [1]

编辑｜泽南 在医疗健康这一容错率极低的领域，大模型不再凭空「想象」，而是已变得严谨可靠、能引会搜：百川刚刚推出的新模型，实现了一个里程碑式的突破。 本周四，百川智能正式发布新一代大模型 Baichuan-M3 Plus，其面向医疗应用开发者，在真实场景下将医学问题推理能力推向了全新高度。新模型发布的 同时，接入 M3 Plus 的百小应 App 与网页版也已同步上线。 在 AI 领域，从来没有一款大模型可以做到 M3 Plus 这么高的医学场景准确率，百川还大幅提升了模型的推理效率，M3 Plus 的发布，标志着 AI 在医疗领 域的应用跨过了「敢用、好用、用得起」的关键门槛。 百川智能创始人、CEO 王小川表示，在垂直领域，M3 Plus 已经可以认为是医生版的 ChatGPT 或 DeepSeek，作为性能最强、推理效率最高的模型，可 大规模用于 AI 辅助医疗落地。 全球最低幻觉率 从看着像，到真的准 长期以来，医生与患者对 AI 的态度一直存在矛盾：人们既期待 AI 能分担繁重的工作，又恐惧它们「一本正经地胡说八道」。信任，是 AI 进入医疗领域的 最后一道墙。 在发布活动中，百川智能模型技术负责人鞠 ...

Core Insights - The investment agreement between Botao Bio's subsidiary Botai Zhito and Hangzhou Haoshi Tianhui marks a significant step in the brain-computer interface (BCI) industry, enhancing the commercial viability of the sector [1][2] Group 1: Investment and Strategic Development - Botai Zhito has completed a strategic investment in Haoshi Tianhui, becoming the sole investor in this financing round [1] - This investment complements Botao Bio's previous strategic stake in Qingshi Yongjun, establishing a dual technology path in both invasive and non-invasive BCI [2] Group 2: Company and Product Overview - Haoshi Tianhui is an innovative high-tech enterprise focused on AI in healthcare, with a strong founding team possessing overseas entrepreneurial experience and deep technical expertise [2] - The company's core AI and non-invasive BCI products aim to create a closed-loop service for various mental health issues, including depression and anxiety, through assessment, intervention, and feedback [2] Group 3: Financial Projections - Revenue forecasts for the company from 2025 to 2027 are projected at 496 million, 693 million, and 887 million yuan, reflecting a year-on-year change of -11.42%, +39.78%, and +28.11% respectively [3] - The net profit attributable to the parent company is expected to be 60 million, 158 million, and 215 million yuan for the same period, with year-on-year changes of -64.49%, +162.50%, and +35.95% respectively [3]

新京报讯（记者陈琳）北京市东城区第十七届人民代表大会第六次会议正在举行。1月14日，东城区卫 生健康委主任曾文军介绍，2025年东城区人均预期寿命达84.59岁，位居全国前列。 强化基层服务能力，开展家庭病床服务试点，开展居家医养联合体试点建设，推动社区卫生与养老服务 资源整合衔接。深化疾控体系改革，推进智慧疾控建设，完善智能监测预警体系，建设区级慢病防治管 理中心。 2025年，东城区医疗资源布局持续优化，医联体建设取得新突破，区第一人民医院新址开诊后门急诊人 次同比增长7%，9家区级医院实现检查检验结果线上共享互认。 基层医疗服务网络进一步夯实，社区医疗机构上转和接收下转人次数同比增长超20%。推动第六医院医 疗集团、和平里医院医疗集团建设，构建网格化医疗服务新格局。在中医药发展方面，东城区获评国家 中医药传承创新发展示范项目试点，打造前门广誉远（600771）"博物馆+国药堂+国医馆"一体化发展 模式，推动"中医药+"融合发展。 在重点人群健康服务上，家庭医生签约服务与居家养老实现深度融合，连续9年获全市基层卫生绩效考 核优秀。针对老年人群，搭建区级老年痴呆全病程服务协作网；保障母婴健康，辖区早孕门诊建 ...

AI 医疗突然成为了这个月的热点。 1 月初 OpenAI 发布医疗产品 ChatGPT Health，Anthropic 推出 Claude for Healthcare，昨天，百川智能正式开源新一代医疗大模型 Baichuan-M3。 评测成绩很突出，在全球最权威的医疗 AI 评测 HealthBench 中以 65.1 分的综合成绩位列全球第一；在专门考验复杂决策能力的 HealthBench Hard 上，也以 44.4 分的成绩夺冠。这一成绩，不仅刷新了 HealthBench 的最高分，更首次在医疗领域实现了对 GPT-5.2 的全面超越。 在 OpenAI 引以为傲的低幻觉领域，M3 也实现了超越，幻觉率 3.5 全球最低。 此外， M3 还首次具备了原生的「端到端」严肃问诊能力 。能像医生一样主动追问、逐层逼近，把关键病史和风险信号问出来，进而在完整的信息上进 行深度医学推理。评测显示，其问诊能力显著高于真人医生的平均水平。 百川的医疗应用「百小应」已同步接入 M3，面向医生与患者开放相关能力。医生可借助它推演问诊与诊疗思路，患者及家属也可通过该应用更系统地理 解诊断、治疗、检查与预后背后的医 ...

Group 1 - OpenAI has announced the acquisition of AI healthcare startup Torch for a total of $100 million, which includes $60 million in cash and $40 million in employee incentives [1][6] - The acquisition aims to enhance OpenAI's commitment to the healthcare sector, integrating Torch's platform with OpenAI's newly launched AI healthcare product, "ChatGPT Health" [4][9] - Torch, founded in January 2025, is developing a unified medical platform that aggregates patient health data from various healthcare systems, allowing users to analyze lab results, prescriptions, and medical records [4][9] Group 2 - Torch's platform distinguishes itself from traditional health apps by categorizing and organizing user-uploaded medical documents, translating medical terminology, and identifying trends in medical data to provide actionable health insights [11] - Currently, Torch is in a limited private testing phase and has not disclosed specific user numbers, but its capabilities are comparable to those of Ant Group's Aifu app, which achieved nearly 14 million downloads in December [11] - The healthcare AI sector is becoming increasingly competitive, with major players like Anthropic also entering the market shortly after OpenAI's launch of ChatGPT Health [11]

智通财经获悉，继推出ChatGPT Health后，OpenAI今日正式宣布完成对医疗保健初创公司Torch的收 购。这家由四名员工于去年创立的企业，专注开发可将实验室检测结果、用药信息及就诊录音等多维度 医疗数据统一整合的解决方案。据公开报道，本次收购交易金额约1亿美元，且Torch全体成员已确认将 加入OpenAI团队。 在微软(MSFT.US)与软银(SFTBY.US)的双重战略支持下，OpenAI于上周正式推出医疗健康领域新产品 ChatGPT Health。据公司官方声明，该产品核心目标在于赋能用户——通过智能化健康管理工具，让用 户对自身健康状态实现"更全面的知情度、更充分的准备度及更坚定的信心"。 Torch 表示："我们创办 Torch，是为了给 AI 构建一份医疗记忆，把分散的记录统一进一个上下文引 擎，帮你看清全貌、串联线索，并确保重要信息不再被噪音淹没。如今，我们加入 OpenAI，以更大规 模实现这一愿景，这是仅凭我们无法做到的。" OpenAI在社交媒体平台X上发布动态称："将这一创新工具与ChatGPT Health深度融合，为理解和管理 个人健康开辟了全新路径。" 过去几年，大型 ...